Urine Tests to Predict Response to Immunotherapy in Kidney Cancer
Studies urine markers that may predict treatment effects in advanced kidney cancer patients.
Plain-language title generated from the registry record
Registry title: Urine Omics Predicting IO Therapy Responses in mRCC Patients
Key facts
- Where
- Taipei, TaiwanSee the site
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT04712305
- Record updated
- 20 January 2022
- Original description
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.Read full original descriptionShow less
Urine Metabolomics and Proteomics Profiling to Predict the Responses and Adverse Events of Immuno-Oncology-based Therapy in Patients With Advanced Renal Cell Carcinoma
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
Inclusion: Age > 20 years; Subjects diagnosed as advanced or metastatic renal cell carcinoma (a/mRCC); Subjects who are about to receive IO-based therapy; ECOG performance 0, 1, 2, and 3; Life expectancy >3 months; eGFR > 15 ml/min/1.73 m2 (Stage IV Chronic Kidney Disease or better); Willing to sign the informed consent form.
Exclusion: Subjects taking any immune-modulating agents, including but not limited to corticosteroid, immune-suppressants, etc. at the discretion of recruiting investigators; Subjects who have taken any IO-based therapy before; Subjects who have received other systemic anti-cancer therapies within 4 weeks of screening are not allowed. However, subjects who had a washout period of the above agents for >4 weeks are allowed to enroll. Subjects who have received or are receiving targeted therapy are allowed to join the study; Subjects having co-existing other malignancies that need active treatment. Those subjects with other malignancies that do not need active treatment are allowed to join the study; Subjects with active infection or active urinary tract infection, as shown by urinary WBC > 5/HPF; Subjects NOT willing to sign the informed consent form.